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European Network of Cancer Registries Working Group on Confidentiality 
 
The Steering Committee of the European Network of Cancer Registries (ENCR) has decided to update the 
guidelines on confidentiality in cancer registries. The last version was published in 2002
1
, three years before the 
endorsement by the European Parliament and Council of the European Directive on the protection of individuals 
with regard to the processing of personal data and on the free movement of such data
2
. The European Directive 
is exhaustive, and is used as an example in many countries. This revision may also have value outside the 
European Union (EU). The EU Directive defines the levels of protection for data on individuals and national 
legislation may further specify these. 
 
The need to revise the guidelines on confidentiality was identified in a European survey of cancer registries
3
. A 
need to expand the guidelines to include ethics and linkages to other databases was also identified. A Working 
Group was formed including specialists in epidemiology, screening, biobanks and clinical databases, under the 
auspices of the EUROCOURSE project. 
 
The terms of reference were: 
 
(a) To update the Guidelines on Confidentiality in the Cancer Registry published by the European Network of 
Cancer Registries in 2002 
 
(b) To include ethics and linkages to other databases. 
 
(c) To examine to what extent these guidelines could be used in cancer registries outside Europe, and to identify 
areas in the guidelines where difficulties may arise. 
 
The members of the Working Group were: 
 
Hans H. Storm, Denmark (Chairman) 
Emanuele Crocetti, Italy 
Timo Hakulinen, Finland 
Alexander Katalinic, Germany 
David Brewster, Scotland 
Michel Coleman, England 
David Forman, IARC 
Mati Rahu, Estonia 
Marc Arbyn, Belgium 
Laufey Tryggvadottir, Iceland 
Sven Törnberg, Sweden 
Evert-Ben van Veen, Holland 
 
Secretariat: 
Mikkel Hyldebrandt Jensen, Danish Cancer Society 
Lone Rosander Thomsen, Danish Cancer Society 
Birgitte Ødegaard, Danish Cancer Society 
 
The Working Group met in Copenhagen and in Lyon to review the guidelines in the light of the European 
Directive. 
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Agreement was reached on the changes required in the light of developments in the law, ethical standards, 
technology, record linkage and cancer registration methods. 
 
We are grateful to all the registries that readily sent copies of the confidentiality rules and codes of conduct from 
their area or from registry associations in their country. Each member of the Working Group took responsibility 
for editing sections of the guidelines. The final version was agreed by all members of the Working Group, 
accepted by the Steering Committee of the ENCR and released in November 2011. 
 
Hans H. Storm 
Chairman, Working Group on Confidentiality of the European Network of Cancer Registries in the framework 
of the EUROCOURSE project. 
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Summary of conclusions and recommendations 
 
A.  Principles of confidentiality and the role of the cancer registry 
 
A.1  The purposes for which data collected by the cancer registry are to be used should be clearly defined 
(section 3.5). 
 
A.2  The legal basis of cancer registration should be clarified and it should be ensured that all reporting bodies 
have legal authority to report cancer, whether registration is compulsory or voluntary (section 3.2). 
 
A.3  The cancer registry must maintain the same standards of confidentiality and ethics as customarily apply to 
the doctor-patient relationship; this obligation extends indefinitely, even after the death of the patient 
(sections 4.1, 4.6 and 4.9). 
 
A.4  Identifiable data may be provided to a clinician for use in the treatment of cancer patients (section 6.3) 
observing that only the data necessary for the stated purpose are released (section 6.2). 
 
A.5  Identifiable data may be transferred to a collaborating or central registry for the purposes of complete and 
accurate cancer registration (section 3.5.2). 
 
A.6  The scope of confidentiality extends not only to identifiable data about data subjects and data suppliers, 
but also to other directly or indirectly identifiable data stored in or provided to the registry (sections 2.5 
and 4.7). 
 
A.7  Data on deceased persons should be subject to the same procedures for confidentiality as data on living 
persons (section.4.6). 
 
A.8  Guidelines for confidentiality apply to all data regardless of storage or transmission media (sections 4.8, 
5.6 and 5.8).  
 
B.  Measures for data confidentiality, protection and security  
 
B.1  The Director of the registry is responsible for data security (section 5.1). 
 
B.2  The staff of the registry should sign, as part of their contract of employment, a declaration that they will 
not release confidential information to unauthorised persons. This declaration should remain in force after 
cessation of employment (section 5.2). 
 
B.3  Suitable control of access to the registry, both physical and electronic, and a list of persons authorised to 
enter the registry, should be maintained by the Director (section 5.4). 
 
B.4  The Director should maintain a list of staff members indicating the nature and extent of their access to 
registry data (section 5.1). 
 
B.5  Notices reminding staff of the need to maintain confidentiality should be prominently displayed (section 
5.3). 
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B.6  Cancer registries should consider providing proof of identity to staff engaged in active registration 
(section 5.5). 
 
B.7  Identifiable data should not be transmitted by any means (post, telephone, electronic) without explicit 
authority from the Director or a staff member to whom such authority has been delegated (section 5.6). 
 
 Transmission by telephone and fax should in general be avoided (section 5.7). 
 
B.8  Cancer registries should consider the use of registered post or courier services for confidential data, as 
well as separating names from other data for transmission (section 5.6.1). 
 
B.9  Precautions should be taken for both physical and electronic security of confidential data sent on 
electronic media (section 5.6.2). This could be by separating identifying (ID) information and tumour-
related data, or via encryption of the ID (section 5.8.1). 
 
B.10  Use of the computer for confidential data should be controlled by electronic and, if possible, physical 
measures to enhance the security of the data, including use of a separate room, use of passwords, different 
levels of access to data, automatic logging of audit trails and all attempts to enter the system, and 
automatic closure of sessions after a period of inactivity (section 5.8.1). 
 
B.11  Demonstrations of the computer system should be performed with separate and fictitious or anonymised 
data sets (section 5.8.2). 
 
B.12 Special precautions should be taken for the physical security of electronic back-up media (section 5.8.3). 
 
B.13  Expert advice on security against unauthorised remote electronic access should be sought if necessary 
(section 5.9). 
 
B.14  Measures should be taken to ensure the physical security of confidential records held on paper and other 
media (section 5.10), and to protect such data from corruption (section 2.8). 
 
B.15  A policy should be developed for the safe disposal of confidential waste (section 5.11). 
 
B.16  Security procedures should be reviewed at suitable intervals, and consideration should be given to 
obtaining specialist advice (section 5.12). 
 
C.  Release and use of registry data 
 
C.1 Appropriate use and release of cancer registry data is central to the utility of the registry. The data may be 
used by the registry and other bodies for a variety of purposes including cancer research, health care 
planning, public health surveillance, and the monitoring and evaluation of interventions. The registry 
should develop suitable procedures for use and release of data that ensure the maintenance of 
confidentiality and ethical standards (sections 3.5 and 6.4). 
 
C.2  The Director of the registry, a scientific committee or an authority should be made responsible for 
deciding if a request for identifiable data meets the requirements of the law, ethical standards and the 
registry‟s guidelines on confidentiality and ethics. Also the scientific soundness of the project should be 
judged (section 6.1). 
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C.3  National legislation with respect to confidential data should be observed. As a general rule, in the absence 
of written consent from data subjects and data suppliers, a cancer registry should not release identifiable 
data on data subjects or data suppliers for purposes other than research and statistics (section 6.2). 
 
C.4  Physicians should be given access to data needed for the management of their patients, if identified as 
such and if in accordance with national law (section 6.3). 
 
C.5  Provision of own data to the data subject must be given upon request, unless a national law exempts such 
a release. It is recommended that data subjects be advised to make the request via their own physician 
(section 6.5). 
 
C.6  Enquiries from the press should be referred to the Director of the registry or to a staff member nominated 
for this purpose (section 6.7). 
 
C.7  Requests for identifiable data to be used for research should include a detailed justification with a 
commitment to adhere to the registry‟s guidelines on confidentiality (section 6.4). 
 
C.8  Registries should provide a document describing their procedures and criteria for the release of data 
(especially identifiable data) to researchers who request access to the data (section 6.4). 
 
C.9  If allowed by national law, cross-border transfer of identifiable individual data should only be carried out 
if required for the conduct of a research project and if the level of protection is satisfactory (section 6.6). 
 
C.10  It is recommended that advance plans should be made for the possible cessation of registry activity, 
including a description of procedures, variables, coding manuals, programs, etc., in order to maintain the 
subsequent utility of the database while safeguarding the confidentiality of its data (section 6.8). 
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1. Purpose of guidelines on confidentiality and ethics in the cancer registry 
 
1.1 Background 
 
These guidelines for confidentiality and ethics in population-based cancer registries in Europe build upon the 
European guidelines published in 2002
1
. They are also consistent with the guidelines first published by the 
International Association of Cancer Registries in 1992
2,3
 and revised in 2004
4
. In brief, the code of 
confidentiality for cancer registries defines the measures to be taken to protect the privacy of the individual 
patient, the doctor and the hospital. They specify what information should be regarded as confidential, and set 
out measures for establishment and periodic review of both physical and electronic security procedures, the 
requirements to be met before release of confidential data for research and other purposes, and the constraints to 
be satisfied by any publication derived from the data. 
 
At the same time it is increasingly being recognised that the ethical standards which apply to epidemiological 
research need to be different from those applying to clinical research on individual patients. Although there may 
be a need to access and/or link individual and personal data, these details are not disclosed, as the fundamental 
nature of epidemiology is group-based statistics
5,6
.  
 
These guidelines are also designed to be consistent with the European Directive on protection of individuals with 
regard to the processing of personal data and on the free movement of such data
7
. That Directive provides the 
basis for national legislation in EU Member States for the protection of individuals with regard to the processing 
of personal data. 
 
Cancer registration procedures have been modified in many countries, moving from paper-based systems to 
systems largely based on computerised data capture and storage
8
. New information technology promises to make 
accurate information more readily available at a lower cost, but it raises concerns from the point of view of 
confidentiality, because of the easy storage and dissemination of huge volumes of data. Despite these concerns, 
there is evidence of strong public support for cancer registration and the use of the data for research
9
.These 
concerns and recommendations related to the protection of electronic health information have been dealt with by 
various committees
10,11,12,13
.  
 
The main objective of guidelines for confidentiality was outlined
14
: (a) to ensure the protection of the 
confidentiality of data about individuals whose cancer is reported to the registry, so the information cannot reach 
unauthorised third parties; (b) to ensure that the cancer registry data are of the best possible quality; (c) and to 
ensure that the best possible use is made of the registry data to the benefit of cancer patients, the population and 
for medical research. A code of confidentiality helps in defining the proper balance between the right to privacy 
for the individual and the right of fellow citizens to benefit from the knowledge on cancer causation, prevention, 
treatment and survival, as derived from cancer registration. Guidelines may make clear to the public how cancer 
registries handle the data entrusted to them in confidence, as well as guiding registries in the creation of 
appropriate safeguards for all aspects of their operation, from data collection to analysis, and the release of data 
for research purposes. 
 
1.2  Aims 
 
The aims of this document are to provide updated guidance on: 
 
a) The definition of terms for cancer registration and confidentiality, with reference to the European Directive 
b) The articles in the Directive that are of particular relevance to cancer registration 
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c) The need for a code of conduct in the maintenance of confidentiality in cancer registration, and the definition 
of what should be considered confidential 
d) The objectives of confidentiality measures in cancer registration, and their legal basis 
e) The principles of confidentiality, including the measures to maintain and survey security procedures 
f) Guidelines for the preservation of confidentiality and ethical standards, for the use and release of registry 
data in accordance with these principles 
 
1.3  European Directive on Data Protection (95/46/EC)
7
  
 
1.3.1 Privacy  
 
The right to privacy with respect to the processing of personal data (e.g. cancer registration) is listed as one of 
the fundamental rights and freedoms of a person, and the protection of this right is the main objective of the 
European Directive. 
 
1.3.2 Explicit consent  
 
Article 7 of the Directive indicates that unambiguous consent is needed for the use of identifiable data about 
persons, unless that use is required by the vital interests or contractual obligations of the data subject, or by legal 
obligations of the data controller, or in the public interest. Article 8 prohibits the processing of data concerning 
health, unless explicit consent is given or other conditions apply see below 1.33. Many uses of registry data, 
however, both in health care planning and in research, involve the release of identifiable data about individuals 
registered with cancer. 
 
If there were no derogations to the principle of explicit consent (see below), the principle would make it virtually 
impossible to use data from a cancer registry, for these reasons: 
 
a) Studies based on cancer registry data often involve hundreds of thousands of cancer patients, and contacting 
every patient would be impossible, especially as in many studies a large proportion would already be 
deceased. The practical burden of seeking consent in this context would therefore be disproportionate. 
b) The repeated burden for patients or their relatives of being asked to consent to the use of their data for 
research is of concern. 
c) Seeking general consent for whatever scientific or statistical use might be made of the cancer registration 
data in the future would impose unacceptable work load on medical personnel and would lead to 
unacceptably low completeness of cancer registration
7
. 
d) From a legal point of view, consent only remains valid for a limited period of time, whereas it is not possible 
to foresee all the research questions that may arise in the future. 
e) Incompleteness of registration would vary between registries as a result of differences in the manner in 
which consent is sought or given. This would invalidate international comparisons of cancer incidence.  
 
1.3.3 Derogation to the requirement for explicit consent  
 
Article 8(3) of the Directive exempts data collection from the requirement for the patient‟s consent if it is: “… 
required for the purposes of preventive medicine, medical diagnosis, the provision of care or treatment or the 
management of healthcare services, and where those data are processed by a health professional subject under 
national law or rules established by national competent bodies to the obligation of professional secrecy or by 
another person also subject to an equivalent obligation of secrecy.” This derogation includes all the components 
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required for cancer registration and most uses of cancer registry data for research. National legislation may add 
further exemptions or restrictions by law or legal order. These do not override the requirement for data 
processing to be „fair and lawful‟ under the Directive. 
 
1.3.4 Derogation to the obligation to inform subjects about data processing  
 
Article 11.1 of the Directive specifies the need to inform the data subject about the disclosure of data to a third 
party when data are disclosed. The registries, however, fall under the derogation in Article 11.2 when processing 
is for statistical, historical or scientific research, or the subjects cannot be informed (deceased persons), or 
provision of information would involve a disproportionate effort, or disclosure of information is allowed by 
national law. In conclusion, cancer registries can operate without informing data subjects about processing and 
disclosure. EU Member States are required to provide appropriate safeguards that must be observed by registries. 
 
1.3.5 Clinical use of data  
 
Data release and use for clinical and screening purposes may be included in the function of some cancer 
registries. These data will usually be supplied to the treating physician or screening organisation and used for the 
benefit of the individual with their informed consent. Such release and use must still be subject to the applicable 
legislation. Information leaflets in screening programmes should inform individuals that their data may be used 
for quality control and research. 
 
1.4  Use of guidelines  
 
In order for cancer registry data to be of value for clinical, statistical and research purposes, the data recorded 
must be as complete, accurate and reliable as prevailing circumstances permit. The data controller has an 
obligation to ensure that the registry data meet these standards of quality. Irrespective of any legislative 
measures, these standards of quality can only be achieved if both the public and the physicians and institutions 
treating cancer patients are confident that the data required are necessary for the objectives of cancer registration 
and medical research, and that confidential data will be adequately safeguarded. 
 
These guidelines are not intended to be adopted en bloc as a fixed set of procedures for the maintenance of 
confidentiality in any particular cancer registry, or without modification to conform to national legislation. 
Rather, they are intended to present the basic principles of confidentiality set out in the European Directive, and 
to provide a set of measures from which a registry may select and reformulate, as appropriate, those measures 
considered to be most useful in the preparation or revision of a local code of practice on confidentiality. 
 
The applicability of these guidelines will continue to be kept under review by the ENCR, and further 
amendments will be made as necessary. 
 
 
2. Definitions 
 
2.1  Cancer  
 
The term „cancer‟ is used in this document to imply all neoplasms and conditions suspected as such, as defined 
in the International Classification of Diseases for Oncology, third edition
15
. Cancer registries always record 
invasive malignant neoplasms, but many also record in situ carcinomas (e.g. cervix, breast, bladder), neoplasms 
of uncertain behaviour and benign tumours (e.g. brain).  
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2.2  Cancer registration  
 
Cancer registration is the process of the continuing, systematic collection of data on the characteristics of the 
neoplasm, the person, the treatment and the outcome, for all persons diagnosed with cancer. It is the basic 
activity of a cancer registry. 
 
2.3  Cancer registry  
 
A cancer registry may be defined as an organisation for the collection, storage, analysis and interpretation of data 
on persons with cancer.  
 
2.3.1 Hospital-based cancer registries  
 
Cancer registries that aim to record information on all cancer patients seen in a given hospital or group of 
hospitals, irrespective of geographical areas, are said to be hospital-based. 
 
2.3.2 Population-based cancer registries  
 
Cancer registries that aim to register details of every cancer that occurs in a defined population, usually those 
persons resident within the boundaries of a defined territory or geographical region, are said to be population-
based. 
 
2.3.3 General cancer registry  
 
A cancer registry may be described as general if all malignant neoplasms are registered. 
 
2.3.4 Specialised cancer registry  
 
A cancer registry may be described as specialised if registration is restricted to neoplasms of a specific type (e.g. 
breast cancer, haematological malignancies) or age group (childhood cancers). 
 
2.4  Data subject 
 
An identified or identifiable natural person, on whom information is processed. 
 
2.5  Confidential data (personal data) 
 
For the purposes of this document, any data collected and stored by a cancer registry that could in theory permit 
the identification of an individual patient‟s (data subject) health data or, in relation to a particular data subject, of 
an individual physician or institution (data supplier), are considered to be confidential. An identifiable person is 
one who can be identified directly or indirectly from a reference number or other identifying information such as 
names, date of birth, etc., or to factors specific to his or her physical, physiological, mental, economic, cultural or 
social identity. 
 
However, the collection of unambiguous identifying information on the data subject is necessary, both in order 
to maintain the quality of the data and for use of the data for research and public health. Anonymisation if used 
must be two-ways, enabling the registry to consult the source data to rectify mistakes or errors. The following 
list provides some examples: 
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a) To avoid duplicate registration of patients visiting more than one healthcare institution 
b) To study cancer survival as a measure of the effectiveness of cancer services; this requires linkage of cancer 
registration with the death registration, which may arise decades after the cancer diagnosis 
c) To study geographical clusters of disease (high-risk areas) 
d) To study the family history of disease, in order to give appropriate advice about familial or genetic risks 
e) To study the late effects of occupational exposures or cancer treatment, by linkage to other health records, 
sometimes many years after diagnosis and treatment of the cancer. 
 
The dates of birth, diagnosis and death are needed for many research purposes. The data items considered 
confidential combined with the health data, either alone or in combination with other data items (x), are listed 
below: 
 
a) Names 
b) Unique reference number (e.g. national identity number) 
c) Address 
d) Full date of birth (x), combined with sex and small-area code for place of residence or death 
e) Date of death (x), combined with sex and small-area code or full date of birth 
f) Small-area code (x), combined with sex and the data items in d) or e) 
 
In many instances, the combination of age, sex, year of diagnosis and small area code may be regarded as 
confidential because a person could be identifiable if the population in the area is sufficiently small. Release of 
such data should be strictly controlled. 
 
2.6  Treating physician 
 
The treating physician is the doctor responsible for the patient‟s treatment: either the primary care physician 
(general practitioner or GP), or the doctor responsible for the patient‟s cancer treatment, or a doctor to whom the 
patient has been referred for additional investigation or treatment. The medical director of the institution at 
which the treating physician is or was employed when treating the patient in question may also act on behalf of 
the physician. 
 
2.7  Security  
 
Security denotes the measures taken to prevent unauthorised access to the registry‟s data, irrespective of the 
medium in which they are stored or transmitted. 
 
2.8  Data protection 
 
Data protection includes both prevention of physical access to the data (security), and protection of the data to 
avoid corruption during many years of storage. Backup procedures for electronic media are also required. The 
term should in this context not be confused with confidentiality (privacy), the aim of which is to protect the 
individual from unauthorised disclosure of data. 
 
2.9  Processing of personal data (European Directive definition)  
 
This denotes any operation or set of operations including data linkages that is performed upon personal data, 
whether or not by automatic means, such as collection, recording, organisation, storage, adaptation or alteration, 
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retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment 
or combination, blocking, and erasure. 
 
2.10  Controller 
 
Denotes the natural or legal person (in this context, usually the Registry Director), public authority, agency or 
any other body that alone determines the purposes and means of processing personal data. When the purposes 
and means of processing are determined by law or regulation, the controller or the specific criteria for his or her 
nomination may be designated by law. 
 
2.11  Processor 
 
In this context, a processor is a natural or legal person, public authority, agency or any other body that processes 
the personal data on behalf of the controller. 
 
2.12  Third party 
 
A third party is any natural or legal person, public authority, agency or any other body except the data subject, 
the controller, the processor and the person who is authorised to process the data under the direct authority of the 
controller or processor. 
 
2.13  Recipient  
 
In this context, a recipient is a natural or a legal person, public authority, agency or any other body to whom data 
are disclosed, whether a third party or not. 
 
2.14  Explicit consent  
 
Explicit consent means any freely given specific and informed decision of the data subject by which the data 
subject signifies his or her agreement to personal data relating to him or her being processed. 
 
2.15  Ethical standards  
 
In the context of these guidelines, ethical standards mean the standards applied to population-based and 
epidemiological research, which differ from the standards applied to the individual doctor-patient relationship, 
but adhere to the standards of the International Epidemiology Association. (Good Epidemiological Practice. IEA 
guidelines for proper conduct in epidemiologic research. November 2007)
16
. 
 
 
3. Role of the cancer registry 
 
3.1  Function of the cancer registry 
 
The cancer registry plays a central role in all aspects of cancer control
17
, not only for the population covered but 
also for other populations with which results can be compared. The systematic collection, recording and analysis 
of data relating to the lifetime of identified individuals with cancer enable analysis and interpretation of clinical 
and pathological characteristics of cancer, cancer incidence, mortality, prevalence, recurrence and survival for 
various population subgroups. It also opens the way for epidemiological research provided that patients can be 
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identified and linked individually to other files, e.g. exposure to carcinogens, biobanks, screening records, 
employment records, etc. The cancer registry has in many countries also proved to be an important tool for 
evaluating and planning health services, in addition to research; again preferably if data can be linked to other 
files, for example, from the hospital and the clinicians involved with the case. 
 
3.2  Legal basis of registration  
 
Cancer registration may be based on compulsory or voluntary notification of cancer patients to the registry. The 
basis for compulsory registration may be legislation passed by a parliament or elected legislative body (primary 
legislation), or an administrative order issued under the aegis of a statutory agency such as the Ministry of 
Health or a provincial health authority. 
 
In some countries, the storage and use of personal data on cancer patients require explicit consent of the data 
subject. However, the European Directive 95/46/EC on the protection of individual‟s rights makes exemption for 
processing done to comply with a legal obligation (Article 7), or when data are required for preventive medicine 
(Article 8.3). 
 
In the same Directive it is explicitly stated (Article 6) that personal data must be processed fairly and lawfully, 
collected for specified purposes, be adequate and relevant for the purpose, be accurate, complete and kept up to 
date, and not kept identifiable longer than necessary for those purposes. Non sensitive personal data for 
historical, statistical and scientific purposes may be processed further (e.g. data linkages), and stored for longer 
periods, provided the Member State provides appropriate safeguards. Such safeguards need not be of a technical 
nature, including complicated organisational and computerised procedures, but may be of a legal nature, with 
supervisory bodies controlling data use and registry procedures as seen in the Nordic countries with data 
inspection agencies. For sensitive data, as stored in cancer registries this can be done in accordance with Articles 
8.3 and 8.4. 
 
Some cancer registries may obtain both voluntary and compulsory notifications, depending on the source of 
information. In some areas, for example, pathologists report voluntarily, whereas the patient‟s physician in 
hospital or general practice is legally required to do so; in others, pathologists are legally required to report 
cancers to the registry, whereas treating physicians report voluntarily. Vital Statistics Offices may be legally 
required to report the vital status, and if deceased, the cause of death on cancer patients. 
 
Fulfilling the legal requirement to „report‟ can mean simply allowing access for registry staff to abstract 
specified information (so-called active cancer registration). It may require, on the other hand, provision of copies 
of various documents from the patient records, on special notification forms, or electronic notification either by a 
dedicated electronic form or by extracting already computerised information. 
 
If the registration is based on data linkage of one or more patient-related registries, vital statistics registries, and 
population registries, legal provision must be in place for the use of such registries for this purpose, and for the 
data items that may be transferred to the cancer registry. Usually this should be stated in the by-laws of the 
registries in question, as well as in the cancer registry by-laws. 
 
3.3  Sources of information 
 
Registries should restrict themselves to the collection of the most important data, of a high quality and 
completeness
14
, and ensure they can link to other databases for various other data items when necessary. 
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Notifications of cancer may be derived from many sources, such as the treating physician, surgeon, radiologist or 
radiotherapist; hospital admissions and records departments, the hospital discharge report, or laboratories of 
pathology, cytology, haematology or biochemistry; medical records of social security systems, private or 
government health insurance systems, hospital patient registries or central patient registries and coroners and 
vital statistics offices (death certificates). Notifications may be submitted on paper records or, increasingly, as 
electronic records, or may be derived from computerised data linkage between e.g. hospital-based patient 
registries, pathology registries and cause of death registries (vital statistics). In some areas, registry employees 
may visit the source of information to obtain notifications (active registration), whereas in others the sources of 
information may submit these directly to the registry (passive registration). Many registries use both active and 
passive methods of registration. 
 
An important part of the information about the data subject comes from population registers, which confirm the 
identity of the data subject, date of birth, address and maybe occupation, and whether the subject belongs to the 
population to be covered by the registry (residency). Follow-up information on deaths or emigrations may also 
come from this source. 
 
3.4  Data items 
 
Cancer registries should observe the principles related to data quality (Directive 95/46/EC Article 6) and collect 
data that are adequate, relevant and not excessive in relation to the purpose, as well as being accurate, complete 
and up to date. The number of data items should thus be limited for two reasons – quality (the fewer data items 
the greater the likelihood that these will be recorded correctly) and confidentiality (the more data items the more 
chance of an unintended breach of confidentiality when releasing data). 
 
The data items in the suggested minimum dataset for cancer registries are listed in Table 1. 
 
Table 1. Items of information collected by registries
14
  
 
 
Essential variables 
Personal identification   Names (in full) AND/OR 
unique personal identification number 
Sex    Male or female 
Date of birth    Day, month, and year 
Address    Usual residence (coded) 
Incidence date   At least month and year 
Most valid basis of diagnosis 
Topography (site) of primary  ICD-O 
Morphology (histology)   ICD-O 
Behaviour    ICD-O 
Source of information 
Recommended variables 
Date of last contact   At least month and year 
Status at last contact   (At least dead or alive) 
Method of first detection 
Stage or extent of disease 
Initial treatment 
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3.5  Use of cancer registry data 
 
The purposes for which data collected by the cancer registry are used should be clearly defined. Cancer registries 
are important sources of data for cancer control
18
. The data are used both for clinical purposes and for research 
intended to advance the understanding of the causes, occurrence and outcome of cancer. However, there is a 
distinction between clinical use and research in the Directive. Clinical use requires information to the data 
subject about processing, and gives the data subject the right to obtain information about him or herself from the 
controller. This is not the case if the cancer registry is using the collected data solely for scientific research or 
statistical purposes (Articles 11, 12 and 13.2). 
 
Data may be either identifiable or aggregate (anonymous), depending on the nature of the research. Some 
examples of the use of cancer registry data in relation to confidentiality are outlined below. The list is not 
intended to be exhaustive, but to identify major categories of use. 
 
3.5.1 Quality of diagnosis, treatment and health care 
 
The clinical use of identifiable data relating to patients registered with cancer arises in context of their diagnosis, 
treatment and follow-up by the treating physician(s). The availability of identifiable data to the treating physician 
is essential to avoid the duplication of diagnostic procedures, to permit the exchange of information between 
treating physicians, and to allow the physician to evaluate the outcome of treatment in individual patients or in 
groups of patients. Identifiable data required for such clinical purposes may therefore be provided to the treating 
physician on request, and in accordance with the procedures outlined in section 6, in order to assist the physician 
in the management of his or her patients with cancer, provided this purpose is included in the registry by-laws. 
Identification of the person is indispensable for these tasks. It is pertinent that the registry and the physician 
observe the confidentiality of the personal information on the data subject during the transmission of data (see 
below). 
 
3.5.2 Transfer of identifiable data for registration purposes 
 
In two circumstances, registries may need to transfer identifiable data to other cancer registries for the purposes 
of complete registration, quality control and the avoidance of duplication. The first case involves a tumour 
diagnosed in a person who proves to be resident in the territory of another, usually adjacent, registry. The second 
case involves regional registries that contribute data to a larger or national registry, or specialised registries that 
also contribute data to a general population-based registry. In each case, data may be transferred for the purposes 
of complete and accurate registration, provided that the recipient registry adheres to comparable standards of 
confidentiality. 
 
3.5.3 Use of identifiable data for cancer control and research 
 
(a) Studies of the causes of cancer 
 
Case–control and cohort studies help identifying the causes of cancer. Both types of study require information 
about individuals with cancer. In a cohort study, for example, linking the cohort members against the cancer 
registry files (or against a file of death certificates) enables cancers and deaths arising in the cohort to be 
detected. This has proved a highly efficient, economical and confidential method of detecting risk. Such linkages 
may be manual, computerised or both, and whereas linkage always requires knowledge of the identity of 
individuals with cancer, irrespective of whether the ID information appears in encrypted form or not (see 5.8.1), 
the resulting publications always present anonymous or aggregated data. It is, however, pertinent for the quality 
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control in such studies that the researcher has the possibility to check the quality of the linkage procedures 
manually and sort out spurious findings, and for these purposes identifiable data must be available. The 
credibility of studies in which such quality control cannot be performed is low, and results in the worst case 
scenario can be misleading. 
 
Registries are frequently used as a source of cases (and sometimes also of controls) for case–control studies. The 
value of these studies for identifying risk factors is enhanced by the availability of a representative sample of 
tumours diagnosed in the population. It must be observed, however, that contact with the data subjects should be 
undertaken through the treating physician or hospital, and with the approval of ethical committees in place in the 
country. 
 
(b) Evaluation of screening  
 
Cancer registries play a major role in the evaluation of screening programmes, by providing information to 
enable the assessment of whether the programme is achieving its goals. In comparison with an unscreened 
population, screening for pre-cancerous lesions of the cervix should decrease the incidence of cervix cancer, 
whereas screening for breast cancer should increase the incidence of early cancer and decrease mortality. The 
cancer registry enables the identification of interval cancers, thus the efficiency of the programme is monitored. 
This requires the comparison of lists of individuals with cancer detected by the screening programme with 
cancer registry files. The cancer registry is thus essential for adequate evaluation of a population-based cancer 
screening programme. 
 
(c) Evaluation of survival from cancer 
 
By matching death certificates to cancer notifications received by the registry, it is possible to assess the survival 
of all persons with cancer in a defined population. Survival from cancer in the population as a whole is 
frequently quite different from that reported for selected series of patients (e.g. in clinical trials). Such data may 
be used to evaluate the extent and speed with which new or improved cancer treatments are incorporated into 
routine clinical practice. It is also possible to assess population survival for a given cancer by the extent of 
spread at diagnosis, or by the type of treatment. This type of research is only possible if the registry can link 
identifiable cancer registrations with death certificates; such evaluation of cancer survival is now routine practice 
in many registries. 
 
3.5.4 Genetic counselling 
 
The use of data in cancer registries on families for genetic counselling of individuals concerned about a possible 
hereditable cancer disease is tempting, because of the completeness of cancer registries and the fact that all the 
necessary data is available in the registry (cancer type, sex, age of family member at cancer and/or death). Such 
use is, however, not readily possible following Article 7 of the Directive, because the counselling cannot be 
considered of „public interest‟ [although inaccurate counselling may lead to overestimation of risks and 
unwarranted consequences, e.g. prophylactic mastectomy], nor are such activities included in Article 8 under 
medical diagnosis and preventive medicine. Therefore, as far as living relatives are concerned, the use of 
registries for genetic counselling can only be on the basis of the informed consent principle.  
 
The policy below was developed by the United Kingdom Association of Cancer Registries:  
 
(i) Request for cancer registry information from registered medical practitioners working in genetic counselling 
clinics concerning living family members, related to a proband undergoing counselling should be accompanied 
by a signed consent form obtained from each family member (or legal guardian) about whom information is 
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requested. The consent form should permit the release to the named registered medical practitioner of 
information relating to cancer from medical and hospital records. The consultant and, when possible, the GP 
responsible for the family member, should be informed about the data release. Information regarding living 
cancer patients should not be released without their signed consent. 
 
(ii) Information regarding patients known to have died can be released to a registered medical practitioner for 
counselling purposes, upon request, without seeking consent. 
 
(iii) Registered medical practitioners receiving cancer registry information must undertake to maintain the 
confidentiality of the data, keep it securely and release it only for counselling purposes. The duty of 
confidentiality relating to medical information extends beyond death, and the above requirements must be 
adhered to for information relating to both living and deceased patients. 
 
(iv) The information released for counselling purposes should consist of the minimum necessary to achieve the 
objectives required. In normal circumstances this would comprise: name, address, date of birth, date of 
diagnosis, cancer site and histology, name of hospital of managing consultants and (for living patients) name and 
address of GP.  
 
The medical practitioner, or other recipient of the data responsible for the request, should sign a declaration to 
the effect that he or she has understood and agrees to act in accordance with the policy statement. 
 
3.5.5 Use of aggregate data 
 
(a) Research and public health surveillance  
 
One of the most important contributions of the cancer registry is to provide current data on the incidence of 
various types of cancer, and on variations in incidence by age, sex, place of birth, occupation, ethnic group, etc. 
These data can also be used to study differences in histological types and between urban and rural areas, and to 
examine trends in incidence over time. Only aggregate, anonymous data are used in such studies after the 
compilation of the dataset during which data are identifiable. 
 
(b) Health care planning  
 
Information provided by the cancer registry on the numbers of cancer patients can help health authorities in 
various ways, including long-term planning for the provision of medical facilities and the training of health care 
professionals; the establishment of priorities and programmes for cancer control; evaluation of the effects of 
intervention; and estimation of the numbers of cancer patients in the future (projections). For most these 
purposes, the identity of individual cancer patients is neither needed nor provided; only aggregate data are used. 
 
 
4. Principles of confidentiality 
 
4.1  Underlying concept of medical confidentiality 
 
The set of principles outlined below relates to the preservation of confidentiality in connection with or during the 
process of collection, storage, use, and transmission of identifiable data by the cancer registry. A cancer registry 
must maintain the same standards of confidentiality in handling identifiable data as customarily apply to the 
doctor-patient relationship; this obligation extends indefinitely, even after the death of the patient. 
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These guidelines are intended to help ensure the confidentiality of data about individuals whose cancer is 
reported to the registry, so that information on registered persons cannot reach unauthorised third parties. 
 
4.2  Sharing of confidential clinical information  
 
For serious diseases such as cancer, „in modern medical practice, the doctor can seldom be the sole confidant, 
since effective care involves others, both medical and nonmedical, technical and clerical, who provide services 
and manage the health care institutions‟19. Despite this essential dispersion of confidential information within the 
clinical team, the ultimate responsibility for the maintenance of confidentiality in the clinical setting remains 
with the treating physician. Therefore, as well as the patient, the treating physician who provides information to 
a cancer registry has the right to expect that the registry observes strict rules of confidentiality (see section 5.1).  
 
4.3  Legal protection of data suppliers  
 
Unless cancer is a disease that must be notified to a cancer registry by virtue of a law or administrative order, the 
data recorded by the cancer registry are supplied on a voluntary basis by the physician or institution. In some 
countries, therefore, it may be necessary for the registry to ensure that there is at least legal authority for 
physicians to report cancer, in order to protect data suppliers from legal action for breach of confidentiality in 
submitting identifiable data to the cancer registry. 
 
4.4  Confidentiality and utility 
 
Effective operation of the cancer registry depends on the continuous supply of confidential information from 
several sources, notably clinicians, pathologists, hospital patient registration systems and vital statistics offices. 
These data suppliers can only be expected to continue to provide such information if the cancer registry can be 
trusted to maintain confidentiality and to make good use of the data. Data suppliers will therefore need to be 
satisfied that the registry adheres to an adequate set of guidelines on confidentiality and ethics, and that data of 
high quality are being collected and used for the benefit of cancer patients, cancer control and cancer research. It 
is important to observe that confidentiality rules follow the intention laid down in the Directive 95/46/EC, and 
are not so strict that the rules will hinder linkage and usage of the data, which again is described in the aims of 
the registry. 
 
4.5  Scope of confidentiality measures 
 
Maintenance of the confidentiality of identifiable data held by the cancer registry should extend beyond 
information on cancer patients and those notifying them (data subjects and data suppliers), to include identifiable 
data from medical records, screening databases, biobanks, census data, interview records, death certificates and 
lists of members of industrial cohorts or other study populations that may be stored in or provided to the cancer 
registry as part of its routine operations or for research projects. 
 
4.6  Confidentiality of data on deceased persons  
 
Data on deceased persons held in the cancer registry should be subject to the same procedures regarding 
confidentiality as data on living persons, even though death certificates or related information may be available 
from other sources. For deceased persons, as for live, information on data disclosure is exempt based on article 
11.2. A supervisory regulatory body may provide sufficient safeguards against breaches of confidentiality for 
deceased persons. 
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4.7  Indirectly identifiable data  
 
Individual records from which names and address have been removed, but from which it might still be possible 
to identify an individual indirectly by the use of the remaining data, e.g. an identity number, should also be 
subject to measures for the preservation of confidentiality in the cancer registry. 
 
4.8  Methods of data storage and transmission  
 
Guidelines for the maintenance of confidentiality are applicable not only to the storage of identifiable data on 
computers, but also to the storage of such data by other means, and their transport or transmission by registry 
personnel in any format. The procedures involved may differ, but the underlying principle is the same. The 
transmission of confidential data by means of electronic media, the Internet or via e-mail must be carried out in 
accordance with the recommendations in sections 5.6 and 5.8 below. 
 
4.9  Ethics 
 
Ethics in medical research are enshrined in the Helsinki Declaration and in the Nuremberg Codes of Conduct. 
The Helsinki Declaration is primarily aimed at protecting individuals subject to invasive, intrusive or potentially 
harmful interventions. Research ethics committees should enable high quality epidemiological research of 
benefit to public health. Ethical evaluation criteria must be appropriate to the type of study (IEA guidelines). For 
example, the basic principle of informed consent, as set out in the European Data Protection Directive, cannot be 
followed for successful cancer registration and large data linkages. It should be noted that the Directive exempts 
cancer registration and public health research from the requirement for explicit consent (1.3.2). 
 
 
5. Measures for data confidentiality and security 
 
5.1  Responsibility 
 
The Director of the cancer registry is usually in legal terms the „controller‟ or the „processor‟ (Directive 
95/46/EC, Articles 2(d) and 2(e)) responsible for maintaining the confidentiality of identifiable data. The 
Director must ensure that the registry staff, and „third parties‟ are aware at all times of their individual 
responsibilities with respect to confidentiality, and that the security measures adopted by the registry are known 
and adhered to. It is recommended that an up-to-date list of staff members and „third parties‟ be maintained, 
indicating the type of data to which each of them has access, and an adequate system of computerised security 
measures (see section 5.8.1). Further fulfilment of the conditions for released data should be followed by the 
Director (see section 6). The specific criteria for the Director‟s nomination (responsibility for data privacy and 
security) may be designated by law. If not, the criteria should be detailed in the Director‟s job description, and 
failure to comply will be considered a breach of the oath of secrecy (see section 5.2). 
 
5.2  Oath of secrecy 
 
Duly trained and specialised staff should be appointed to run the cancer registry in accordance with its aims and 
rules of operation. It is recommended that, as part of their contract of employment or conditions of service, each 
member of the registry staff be required to sign a special declaration to the effect that they will not disclose 
confidential information held by the cancer registry, or brought to their attention in the line of work (e.g. active 
registration) to an unauthorised person at any time, or to any other person except as permitted within the context 
of the registry‟s guidelines on confidentiality. The terms of the contract of employment should make it clear that 
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a breach of this undertaking will result in disciplinary action, which may involve dismissal. Furthermore, it 
should be made clear that a dismissal on these grounds will be disclosed to employers within the health sector if 
so requested, thereby making the oath of secrecy comparable to the professional medical oath of secrecy. This 
declaration of secrecy shall remain in effect even after the staff member ceases to be employed in the cancer 
registry. For staff involved in active cancer registration (see section 5.5), it is recommended that they are made 
aware of, and sign, the confidentiality rules of each data provider, and that these rules and declarations are 
attached to the general oath of secrecy kept in the registry. 
 
5.3  Display of reminders 
 
It is recommended that notices reminding staff of the need to maintain confidentiality be prominently displayed 
within the registry.  
 
5.4  Physical access to the registry 
 
Unauthorised access should be prevented. Physical access to the registry premises has to be restricted by 
adequate technical safeguards. Suitable locks and alarm systems should be installed to control physical access to 
the registry. Consideration should be given to the use of special locks with entry codes, or electronic methods of 
controlling access, and to the maintenance of a record of persons other than staff members who enter the 
registry. The Director of the registry should maintain an up-to-date list of all persons authorised to enter the 
registry. 
 
5.5  Active registration 
 
Registry staff assigned to collect information at source (active registration) are responsible for maintaining the 
confidentiality not only of identifiable data they may collect on persons with cancer for the registry, but also of 
other information of a confidential nature that they may read or hear at the source (see section 5.2). 
 
Cancer registries using active methods of registration should give consideration to the safe transport of 
confidential information (see section 5.6), measures to avoid the accidental loss of such material, e.g. by keeping 
a backup at the source, and to providing staff with suitable means of identification as an employee of the cancer 
registry.  
 
The identity of such staff should be made known to the relevant person(s) at each of the sources that they visit to 
collect information for the registry, and where possible, changes in personnel should be notified to these sources 
in advance. 
 
5.6  Transmission of information  
 
Authority to transmit identifiable data from the registry, irrespective of the method, must be given by the 
Director (controller) or other nominated staff member to whom specific responsibility for such transmission has 
been delegated (processor) (Directive 95/46/EC, Articles 2(d) and 2(e)).  
 
5.6.1 Postal and courier services 
 
If postal or courier services are needed for transfer of confidential information, be it on paper or electronic 
media, consideration should be given to the use of registered post or other forms of recorded acceptance and 
delivery by the service. The ID information should be mailed separately from the health information, to be 
combined using an internal code number by authorised staff upon receipt of both mailings.  
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For data on electronic media (e.g. CD, DVD, memory sticks), the encryption of ID information with a special 
key is an alternative to the procedure of two separate mailings (see also section 5.8.1). 
 
The use of double envelopes, the external envelope giving a general address, and the internal envelope being 
marked for opening only by a named individual is a precaution against accidental access to the information by 
unauthorised personnel. 
 
If a courier service is officially authorised to handle confidential data and is used, the registry may consider if 
derogation from the separate mailing and encryption is acceptable. 
 
5.6.2 Electronic data transmission  
 
When identifiable data are sent electronically, suitable precautions should be taken to ensure the physical 
security and the confidentiality of the material in transit. In addition to the steps taken to ensure that the data 
cannot easily be read by an unauthorised person, measures to check for incorrect or corrupt files must also be 
taken (Directive 95/46/EC Article 17). Among the precautions that might be taken are: 
 
(a) Ensuring that the address of the recipient is correct. The risk of sending to the wrong recipient may be 
reduced by using different media for contact before sending any data or ID key. 
 
(b) Encrypting of names and other ID information at various levels of complexity, with a special key only 
available to authorised users (see also section 5.8.1). 
 
(c) Sending data files, the identifiable data should be sent separately from the other data, using a link number to 
enable the reconstitution of the record by the intended recipient. This may also be achieved by using different 
media for ID and data files.  
 
(d) Transmitting data can be achieved by download of data through a secured, encrypted FTP (file transfer 
protocol) where the access code and instructions are transmitted in accordance with (a). 
 
(e) Including tabulations and counts by which the content of the transferred data can be checked, and the 
program written to produce the tabulations and counts. 
 
(f) Requesting the recipient to confirm safe receipt of the data and their integrity 
 
5.6.3 Processing and matching of data by external agencies 
 
The registry files may need to be processed or matched against other computer files, either to provide missing 
data items or for the purposes of research. If it is necessary for such processing to be undertaken outside the 
registry, e.g. in a vital statistics office or on an external computer, or in another country (see also section 6.6), the 
registry must ensure that the confidentiality of its records will be preserved by the agency receiving the registry 
data and that the measure complies with the national law (95/46/EC Article 4). Transmission should be in 
accordance with the above procedures. 
 
Any unnecessary transfer of identifiable data outside the registry should be avoided. Alternatively, data may be 
provided with a key for identifying individuals and the key kept at the cancer registry. 
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5.7  Use of telephone and fax 
 
It must be clearly recognised that use of the telephone, although convenient, may easily give rise to a breach of 
confidentiality. It is under normal circumstances virtually impossible to document the content of a telephone 
conversation; hence it is difficult to handle in legal terms. 
 
As a general rule, no identifiable data or confidential information of any kind should be given to telephone 
callers or by fax by registry staff, nor should the registry staff seek information in this way. If a fax is used, it 
should be a “safe haven” fax. The fax number should be checked carefully before transmission. 
 
The need for the registry to pass identifiable information to external callers by telephone should be infrequent. 
Registry staff should be alert to attempts to access patient information fraudulently. In rare instances in which 
the telephone method can be justified by the Director, the identity of the caller (name, position, title and address) 
must be checked and a call-back procedure followed, using only officially published telephone numbers. 
 
5.8  Use of computer  
 
Physical and electronic measures should be used to prevent unauthorised access to information held on the 
computer. Technical measures administered for the sake of data protection should not lead to a compromise in 
the quality of the basic data or make the use of the data unacceptably difficult or expensive. 
 
Electronic measures are subject to rapid evolution, and better solutions may emerge than those discussed in 
general terms here. 
 
5.8.1 Access to data  
 
(a) Workstations used for data access should be placed in a separate room(s), access to which is restricted. 
 
(b) Passwords should be sufficiently complex and should not appear on the screen when typed. Automatic 
storage of passwords linked to user name should be disabled. 
 
(c) Passwords should be changed at intervals, and minimum requirements for changes (interval and password) 
stated in the registry code for confidentiality. 
 
(d) An automatic log (audit trail) should be kept by the computer of all successful and unsuccessful attempts to 
enter the system, and session activity by authorised users. The Director should authorise a limited number of 
persons to have access to the audit trail. 
 
(e) Different levels of access to the database, supported by password protection and user recognition, should be 
defined, so that only users authorised to gain access to identifiable data can do so. The Director should keep 
an updated list of persons allowed each access level. 
 
(f) Sessions which have been inactive for more than 10 minutes should be automatically closed, and instructions 
given to staff to close sessions immediately after use. 
 
(g) The computers of the cancer registry should be in one environment protected by a firewall. 
 
(h) Encryption of data has been proposed for preserving confidentiality in storage and communication of 
confidential data
20
. 
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The matching and linking of encrypted individuals however need great care, as errors may also be encrypted. 
Only limited experience exists with these methods in cancer registries. So far fully functioning systems have not 
been developed. 
 
One other method to increase the difficulty of unauthorised use is the separation of the identity information and 
the cancer data.  
 
(i) All testing of new hardware and software should be carried out with special test data. Electronic storage 
media must be efficiently erased or destroyed when taken out of use. 
 
5.8.2 Demonstrations  
 
When the database and the computer system are demonstrated, fictitious or anonymised data should be utilised. 
Screen displays should be labelled appropriately to make visitors aware of this. A special data set for 
demonstrations is recommended. 
 
5.8.3 Back-up 
 
Back-up copies of the database and its changes should be made frequently and regularly as a protection to avoid 
the loss of the database, and should be stored in a physically separate, secure location, ideally in a water and fire-
proof safe. Previous versions of back-up copies should be converted to enable reading when technology changes. 
 
5.9  Unauthorised access to computer system 
 
It must be recognised that some persons may attempt to gain remote electronic access to computer systems, often 
to show that this is possible rather than to examine the data. It is unlikely that registries using computer systems 
to which remote electronic access is possible can provide absolute protection against any such attempt. The level 
of security built into such systems should at least be capable of foiling casual attempts to gain unauthorised 
access. Consideration should also be given to obtaining expert advice on enhancing the electronic security of 
such computer systems; this aspect of security should be regularly reviewed (see section 5.12). Although it may 
not always be possible, it is preferable that the cancer registry has an isolated data processing system. 
 
5.10  Storage of original data  
 
Electronic methods of storage of identifiable, validated and coded data in cancer registries are now almost 
universal. Original data received on paper should stay in a paper file or be image scanned to password-protected 
electronic media. Such material may include cancer registry notification forms, medical records, copies of 
pathology reports, copies of death certificates, etc. It is recommended that the original data be preserved for 
quality control and research purposes, in line with the code of good conduct of the International Epidemiology 
Association for other research data. The storage of records on paper should be reduced to a minimum for both 
confidentiality and practical reasons. Paper records are accessible to casual inspection, and require no special 
expertise to gain access. Specific measures for „paper records‟ that may be considered include: 
 
(a) Defining who has access to the registry premises. 
 
(b) Defining which members of staff have access to the room where these materials are kept.  
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(c) Providing lockable storage cabinets in which all confidential materials should be stored at the end of a 
working session. 
 
(d) Ensuring that persons not authorised to do so (e.g. cleaning personnel) are not able to scrutinise paper or 
other physical records containing confidential data. 
 
5.11  Disposal of physical records 
 
A suitable policy should be developed for the safe disposal of waste paper and other physical records containing 
identifiable data, be it computer output or original data copied to other media. The destruction of paper would 
normally involve shredding. This should preferably be performed within the premises of the registry. When the 
volume of confidential records to be destroyed is large, it may be necessary to employ specialised and officially 
authorised services for the safe disposal of confidential waste. 
 
(For disposal of electronic records see 5.8.1 (i)) 
 
5.12  Review of confidentiality and security procedures  
 
It is recommended that cancer registries undertake formal review of their security procedures annually, and at 
the same occasion revise access files and logs. It may be helpful at 5-year intervals to recruit the services of 
specialist advisers to ensure that the registry‟s procedures for the maintenance of confidentiality are up to date, 
and cover all aspects of the registry‟s operations. 
 
 
6. Release of data 
 
- As a general rule, only data to a specificity needed for the question raised should be released. 
 
- The release of aggregate data, in tabular or equivalent formats, and anonymised data does not usually breach 
confidentiality.  
 
- Care should be taken that an individual may not potentially be identified from such data, e.g. by date of birth 
(age), sex, and residence in a small geographical area. 
 
An example of disclosure control guidance is available at  
www.statistics.gov.uk/about/data/disclosure/downloads/confidentiality-guidance.pdf 
 
Many of the uses of registry data, especially in research and quality control for e.g. screening, involve the release 
of identifiable data on individuals registered with cancer. The derogations to the European Directive 95/46/EC 
(Articles 8.3 and 8.4, and further explained in recital 34 of the Directive) can be applied in order to legalise the 
use and the release of data for preventive medicine, including „public health purposes and scientific research‟. 
National legislation may in the public interest by law or legal order add further exemptions. 
 
Furthermore, the Directive 95/46/EC (Article 11.1) specifies the need to inform the data subject about the 
disclosure of data to a third party at the time when data are disclosed. The registries have, however, derogation in 
Article 11.2 when the processing is for statistical, historical or scientific research, and the provision of 
information is impossible (deceased persons) or involves a disproportionate effort or national law allows the 
disclosure. Member states shall in these cases provide appropriate safeguards that must be observed by registries. 
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Procedures must be developed to deal with requests for the release of confidential data. Examples of such 
procedures are given below. 
 
6.1  Responsibility for data release  
 
The Director (controller) ensures that the law and national guidelines including ethical standards are followed 
and confidentiality is preserved when data are released. The research projects for which the data are to be 
released should be scientifically sound. A mechanism to decide about what can be regarded as sound should be 
established. The director, a scientific committee or an authority could be made responsible for that decision. 
 
- It is adviced have a data transfer agreement signed with the receiving part of the data, specifying the terms 
for use and publication of the data. 
 
6.2  Limitations on data release 
 
(a) National legislation with respect to data confidentiality, patients‟ rights etc. should be observed. 
 
(b) In the absence of written consent from all the parties concerned, a cancer registry should not release 
identifiable data either about a registered person (data subject) or, in relation to such a person, about a 
treating physician or institution (data supplier), for any purpose other than those outlined for clinical and 
research purposes (section 3.5). 
 
(c) The data released should be limited to the variables needed for the stated purpose. 
 
(d) Requests for information, even from physicians, may be received for identifiable data concerning individuals 
(who may or may not have a cancer recorded at the registry), from agencies such as pension schemes, health 
care cost reimbursement schemes or industrial disease compensation panels, or in the context of medical 
examination for life insurance or employment. Such requests should be refused, and the enquirer should be 
asked to obtain information directly from the subject or the subject‟s treating physician.  
 
6.3  Release of identifiable data for clinical purposes 
 
Access to identifiable data in the context of treating a patient registered with cancer should be given to the 
treating physician, subject to the legislature concerning the transfer and release of medical (clinical) data in the 
country. 
 
6.4  Release of identifiable data for scientific and cancer control purposes  
 
The registry should prepare a public, written document that sets out the criteria and procedures applicable to the 
release of its data, particularly the release of identifiable data for research. This document could be provided to 
researchers requesting identifiable data, including a model transfer agreement (see 6.1) and reference made to 
any national legal and ethical requirements. 
 
A request for the release of confidential data should be made in writing to the supervising authority. The release 
should fall within the accepted uses of registry data and the requirements for safeguarding the confidentiality of 
the data. 
 
The request should include: 
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(a) The purpose for which the data are needed. 
 
(b) The information required, and a justification of the need for confidential data. 
 
(c) The name and position of the person in  charge of the data after their release. 
 
(d) The name and position of other persons who will have access to the data after their release. 
 
(e) The period of time for which the data would be used, the way the data would be handled and the way in 
which the data (with all its copies) would be disposed of, returned or destroyed after this period has elapsed. 
 
The requesting party should also make an assurance to the cancer registry director or the body in charge of data 
release, by verified signature that the intended recipient of the identifiable data will: 
 
(f) Observe the same principles and obey the same laws as are observed and obeyed by the staff of the cancer 
registry. 
 
(g) Comply with all restrictions on the use of the data imposed by the registry, in particular that the data will not 
be used for purposes other than those agreed upon at the time of the provision of the data, and that they will 
not be communicated to other parties. 
 
(h) Not contact registered persons (or their relatives) whose identities have been provided in confidence by the 
cancer registry (e.g. for research based on interviews) unless a written authorisation to do so has first been 
obtained from the treating physician. When appropriate, approvals by ethics committees should also be 
sought. 
 
(i) Ensure that no publication of the results will enable any individual to be identified.   
 
(j) Report in writing to the cancer registry director when the data are disposed of, returned or destroyed as 
agreed.  
 
(k) Give due acknowledgement to the registry for provision of the data. 
 
(l) Provide the registry with a copy of all published and pertinent results when accepted for publication or, if not 
published, at the time of disposal of the data. 
 
6.5  Provision of data to individuals 
 
If the cancer registry holds the full ID of the patients; registries are obliged, upon request at reasonable intervals, 
without excessive delay and expense, to inform a data subject whether or not data relating to him or her are in 
the cancer registry. The information should contain the purpose, the categories of data (variables) and categories 
of the recipients of the data (Directive 95/46/EC Article 12). If a national law explicitly exempts the controller 
from releasing information to the data subject, or the data are being processed solely for scientific research 
(Directive 95/46/EC Article 13) this obligation does not apply. 
 
It is recommended that such data are released either through the treating physician or by registered mail to the 
data subject using double envelopes, a sealed one containing the print-out of the registry data and in the main 
envelope an accompanying letter advising the data subject to consult a physician when breaking the seal. The 
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reason for this is to avoid causing unwarranted anxiety to the patient and to ensure that they obtain medical 
advice and support when interpreting the information. 
 
6.6  Transfer of data across borders  
 
One of the reasons for the European Directive 95/46/EC is the expected increase in scientific and technical 
cooperation (recital 6). The Directive 95/46/EC on the protection of individuals with regard to the processing of 
personal data and on the free movement of such data regulates the cross-border flow of data in a consistent 
manner, and safeguards the fundamental rights of individuals. Furthermore, the Directive should lead to an 
approximation of national laws, and secure a similar and higher level of protection for the rights and freedoms of 
individuals, and in particular the right to privacy. Within the European Union the processing of personal data is 
governed by the laws of the member state in which the data is processed (machines, software). In principle 
personal data can be transferred, but should only be done when necessary. When the study design requires that 
identifiable data be transmitted across registry or national borders this can be done within the European Union 
and EFTA. Outside these countries, if national legislation permits and the level of protection satisfies Article 25 
of the Directive, then such data can be transferred. The data should at least remain subject to the same rules of 
confidentiality as in the registry of origin. Cancer registries participating in such studies should satisfy 
themselves that their data will be treated accordingly, and seek approval for the transfer with national authorities.  
 
The transfer of personal data to third countries (Article 25) is also allowed if the country complies with the 
national provisions for confidentiality and the European Directive, and if the country in question can afford an 
adequate level of protection, which has been assessed by a member state of the European Union. A derogation 
(Article 26.1(d)) from these requirements can be made if the transfer is necessary on important public interest 
grounds. 
 
Research projects involving the provision of data about individuals from many cancer registries, sometimes in 
different countries; have provided valuable information about cancer risk. Although it may be necessary for 
individuals to be identifiable within the context of such studies, identifiable data should not normally be 
transmitted to other registries or countries. Each subject may be allocated a suitable number by which his or her 
record can be traced in the cancer registry of origin by registry staff, for data verification within the study. This 
number can then be used instead of the subject‟s identity in data files contributed to the study coordinating 
centre. It should, however, be observed that the data in legal terms are still personal and identifiable. 
 
6.7  News media 
 
Cancer registries are frequently approached by the press for information on cancer. It is recommended that all 
such enquiries be referred to the Director or other nominated staff member, to whom specific responsibility for 
dealing with the press has been delegated. 
 
Great care should be taken not to disclose any personal data, or data that by linkage to other data may disclose 
the identity of individuals (such as sex, age, small area) to the media.  
 
6.8  Cessation of cancer registration  
 
Each cancer registry should develop a policy for the actions to be taken in the event that the registry ceases 
operation. Consideration should be given to methods of storage of the registry database in an archive, so as to 
preserve its utility for the purposes outlined above (section 3.5), while ensuring the maintenance of 
confidentiality. It is recommended that, where possible, a suitable agency such as the national or regional 
archives regulated by law be identified, in advance, to store the registry archive, a registry description including 
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data capture and handling, description of variables, quality control measures, code manuals, definitions and 
computer programs used, and a description of the structure of the archived file for a minimum of 50 years. The 
archive should undertake to make the database available for the purposes defined by the registry and under the 
same rules of confidentiality as applied by the registry. Consideration should also be given to the data selected 
for storage and the method of archiving. Selected paper records might be microfilmed or image scanned, and 
selected computer files archived on electronic media. The safe disposal of confidential records not included in an 
archive deposit should also be planned in advance. 
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APPENDIX 
 
Confidentiality issues regarding population based cancer screening monitoring systems and registries. 
 
Screening for cancer is a prevention strategy with the aim of early detection of presumptive lethal disease in 
order to  decrease morbidity and mortality of cancer. Screening is an intervention towards a ”healthy”  
population and although the individual person may perceive the benefit it can only be measured in terms of 
decreased morbidity and mortality in the population. Negative side-effects like false positive outcome, or false 
reassurance, worry and anxiety related to the testing is an ethical concern hence the WHO  guidelines for 
implementing screening must be adhered to (1)- 
(http://www.who.int/cancer/detection/variouscancer/en/index.html). In addition to these it is only ethical to 
intervene with screening in a population  if the screening is organised and there is  access to relevant data at an 
individual level enabling to ascertain the quality and optimal outcome of the entire screening process.  
The European Council recommends population-based screening for cancer of the cervix uteri, breast in women 
and of for colorectal cancer in women and men offered in organised programmes in agreement with evidence 
based guidelines (2-4).  
A screening registry is the cornerstone of a population based and centrally organised screening programme. 
The purposes is to have a monitoring system for the quality assurance and audit of the screening programme 
with access to the target population and the ability to store data on the entire chain at an individual level from 
invitation to participation and testing, further assessment and treatment. In the absence of population based 
cancer registries also to evaluate the effect and the long term results and form the basis for research.It should 
contain relevant data on screened individuals (such as: unique ID, sex, birth date, residence, the date and 
results of the screening tests and follow-up examinations).  The role of a cancer screening registry in the 
framework of a comprehensive cancer prevention policy is described in Table X.  To fulfil its full role, the 
screening registry should contain all screen test results and not only the positive cases. All screened individuals 
should be entered irrespective of their age or the type of screening (organised or opportunistic). 
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Table X. Role of a cancer screening monitoring system and registrer:  
 Monitoring of the entire screening process 
 Direct service to citizens: 
o invitation of individuals belonging to the target population to attend for a 
screening: call system (invitation of all individuals of the target age group) or call-
recall (invitation of individuals of the target age group who did not have a known 
recent screening test), 
o fail-safe system to recover screen-positive individuals lacking follow-up,  
o information to GPs and other health professionals with respect to the screening 
status and history of their patients.  
 Process evaluation: 
o response rate to invitation, screening coverage, 
o distribution of screen test results, positive predictive value of positive screen tests, 
detection of cancer or high-grade cancer precursors; compliance with 
recommended follow, 
 Impact evaluation 
o audit of cancer cases 
o comparison of interval cancer rate, cancer rate among non-screened populations 
o effectiveness of cancer screening using a case-control study design (screening and 
follow-up history of cancer cases versus matched controls without cancer)  
 
A screening registry should be linkable with population files, follow-up registries (colposcopy; colonoscopy; 
additional imaging, histological biopsies; therapeutic interventions), HPV vaccination registries, the national or 
regional cancer registry, biobanks (cell or tissue specimen of cervix, colon, breast) and mortality registries.  A 
unique ID is needed allowing these linkages if accepted by the relevant controlling bodies in accordance with 
the derogations to the data protection Directive 95/46/EC. 
 
The confidentiality principles for cancer registries should be applied for screening registries as well.  However, a 
more comprehensive legislative framework as foreseen in the European Council recommendation may be 
needed since screening registries comprise not only cancer patients but the whole population of certain target 
age groups, with the large majority being healthy and not presenting symptoms.   
A screening registry must operate in agreement with national privacy legislation, laws regulating biobank 
practice and patient rights. Informed consent or opt-out are two possible procedures assuring that screening 
data never are registered outside control of the individual concerned. In the former, a priori absence of 
consent and, in the latter, automatic consent, unless explicit refusal, are assumed.  In Belgium cancer screening 
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data is recognised in the privacy protection law as an example where such derogation is accepted (5) alongside 
the obligatory registration of all cytopathological results in the framework of early detection of cancer (6).  
In Sweden, access to individual data on the entire population is approved for the reason of equality and quality 
assurance of all phases of a screening programme in order to ensure the population of equal access to the 
screening programme and equal access to optimal assessment, treatment and follow-up. When data in a 
screening register is used for such purposes, they are regarded as patient records and the register as a care 
register. When a same register is used for other purposes e.g., research or evaluation at a group level, data are 
regarded as quality data and the register as a quality register and access would not be allowed without an 
approval from an Ethical Board. M. Arbyn (Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, 
Belgium 
S. Törnberg (Stockholm, Sweden) 
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